A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
Stopped early · Phase 1
Conditions studied: Breast Cancer, Colorectal Cancer, Uveal Melanoma, Cutaneous Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
In brief
A multicenter trial to investigate TBio-4101, an autologous, neoantigen-selected, tumor-reactive TIL product, in patients with advanced solid malignancies.
Key facts
- Study ID
- NCT05576077
- Run by
- Turnstone Biologics, Corp.
- People needed
- 31
- Starts
- 2023-01-17
- Expected to finish
- 2025-02-24
- Last updated by the study team
- 2025-03-10
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Orlando Health — Orlando, Florida, United States
- University of California Irvine — Irvine, California, United States
- Memorial Healthcare System — Hollywood, Florida, United States
- University of Miami — Miami, Florida, United States
- Moffitt Cancer Center — Tampa, Florida, United States
- University of Chicago — Chicago, Illinois, United States
- Norton Cancer Institute — Louisville, Kentucky, United States
- Providence Cancer Institute — Portland, Oregon, United States
- Allegheny Research Institute — Pittsburgh, Pennsylvania, United States
- MD Anderson Cancer Center — Houston, Texas, United States
- Medical College of Wisconsin — Milwaukee, Wisconsin, United States
- Princess Margaret Cancer Centre — Toronto, Ontario, Canada
- Montreal University Hospital Center — Montreal, Quebec, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.